Researchers at Nyu Langone Health and his Perlmutter Cancer Center have revealed that blood tests could predict the return of skin cancer.
According to the American Cancer Society, melanoma is a less common form of skin cancer that is more dangerous than other varieties.
This is due to the fact that it is much more likely to extend to other parts of the body, if it is not found and it is treated early.
The cancer report reveals amazing new data on deaths, diagnostics
The new cancer research, published in the Oncology Journal, examined the levels of circulating tumor DNA (CTDNA) in the blood of patients with cancer.
About 80% of patients with melanoma of phase 3 that had detectable adna levels experienced a return of cancer later. (Istock)
About 80% of patients with phase 3 melanoma had detectable levels of ADNA (before starting treatment) experienced a return of cancer later, according to a statement by Nyu Langone.
The melanoma of stage 3, one of the most aggressive forms of skin cancer, occurs when the cancer has spread to the lymph nodes.
Popular coffee alternative can help prevent cancer, according to experts
Researchers said that lymph nodes could be removed surgically, but once they have disappeared, this makes it harder to control cancer through traditional methods such as X and TC rays.
This challenge has led to an interest in finding new ways to detect cancer activity sooner.
Melanoma is a less common form of skin cancer more dangerous than other varieties due to the speed that is spread. (Istock)
“Our results suggest that circulating tumor DNA tests could help oncologists identify which patients with melanoma are more likely to respond well to therapy,” said main author Mahrukh Syeda in the statement.
Early detection of the return of the disease through ADNA analysis could save lives, according to Syeda, as this type of cancer is notoriously difficult to treat once it has been extended.
“DNA tumor testing tests provide a clear and direct measure of the disease itself.”
The study analyzed the results of about 600 men and women who participated in a previous clinical trial. The researchers used blood samples to compare the presence of ADNA and the evidence of the return of cancer.
The team represented other factors such as sex, age and type of therapy used to combat cancer.
The common medical test related to 5% of cancers, the study suggests: “Use -wise them”
Almost all patients who had detectable adna levels in a year after treatment experienced a return from melanoma.
“The atdna method works focusing on the most common mutations of the genetic code on the melanoma cells,” according to the launch.
Researchers found that almost all patients who had detectable adna levels in a year after treatment experienced a return from melanoma. (Istock)
The evaluation of ADNA levels was so good or better to predict the recurrence that other evidence that involves examining the tumor itself, found researchers.
“Unlike standard and tissue -based tissue -based analyzes, which may only suggest the likelihood of recurrence, circulating tumor DNA tests provide a clear and direct measure of the disease, and can directly tell us that melanoma has returned,” said senior author and dermatologist David Polsky in the press statement.
Click here to register -you are in our health newsletter
In some cases, however, cancer still returned, although patients had negative ADNA tests before therapy began.
Researchers are planning to improve the sensitivity of tests in the next study in the hope of reducing cases like these.
“It shows that the tumor DNA that circulates persistent after healing surgery is a poor prognosis, which suggests a high risk for early recurrence.” (Istock)
Dr. Joshua Strauss, a hematologist and medical oncologist attending Advanced Care Oncology and Hematology Associates from the Atlantic Medical Group in Morristown, New Jersey, applauded the research.
Click here to get the Fox News app
“This is another in a line of study offered by the powerful technologies that are now able to detect the tumor DNA that circulates in the blood in various types of tumors,” Fox News Digital told.
For more health items, visit www.foxnews.com/health
“It is clear from this work that the DNA of the tumor that circulates persistent after healing surgery is a poor prognosis, which suggests a high risk for early recurrence,” Strauss continued.
The next step in the evolution of this technology, according to the oncologist, will be to use this information “not only in a forecast, but in a predictive way to help guide management options”.
#Blood #pots #predict #recurrence #skin #cancer #studies
Image Source : www.foxnews.com